Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:platinum-based_antineoplastic_agent
gptkb:chemical_compound |
| gptkbp:approvalYear |
1989
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XA02
|
| gptkbp:CASNumber |
41575-94-4
|
| gptkbp:commonName |
gptkb:carboplatin
|
| gptkbp:developedAsAlternativeTo |
gptkb:cisplatin
|
| gptkbp:discoveredBy |
gptkb:Johnson_Matthey
|
| gptkbp:hasMolecularFormula |
C6H12N2O4Pt
|
| gptkbp:isLessToxicThan |
gptkb:cisplatin
|
| gptkbp:IUPACName |
gptkb:cis-diammine(cyclobutane-1,1-dicarboxylato)platinum(II)
|
| gptkbp:meltingPoint |
> 250°C
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
nausea
vomiting myelosuppression nephrotoxicity (less than cisplatin) ototoxicity (less than cisplatin) |
| gptkbp:synonym |
JM-8
NSC 241240 |
| gptkbp:usedFor |
gptkb:cancer
gptkb:bladder_cancer gptkb:testicular_cancer head and neck cancer cancer chemotherapy |
| gptkbp:bfsParent |
gptkb:carboplatin
|
| gptkbp:bfsLayer |
7
|
| https://www.w3.org/2000/01/rdf-schema#label |
CBDCA
|